344 related articles for article (PubMed ID: 26132471)
21. E2F1-specific induction of apoptosis and p53 accumulation, which is blocked by Mdm2.
Kowalik TF; DeGregori J; Leone G; Jakoi L; Nevins JR
Cell Growth Differ; 1998 Feb; 9(2):113-8. PubMed ID: 9486847
[TBL] [Abstract][Full Text] [Related]
22. TAp73 alpha increases p53 tumor suppressor activity in thyroid cancer cells via the inhibition of Mdm2-mediated degradation.
Malaguarnera R; Vella V; Pandini G; Sanfilippo M; Pezzino V; Vigneri R; Frasca F
Mol Cancer Res; 2008 Jan; 6(1):64-77. PubMed ID: 18234963
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA-340 inhibits prostate cancer cell proliferation and metastasis by targeting the MDM2-p53 pathway.
Huang K; Tang Y; He L; Dai Y
Oncol Rep; 2016 Feb; 35(2):887-95. PubMed ID: 26718483
[TBL] [Abstract][Full Text] [Related]
24. Dmp1 physically interacts with p53 and positively regulates p53's stability, nuclear localization, and function.
Frazier DP; Kendig RD; Kai F; Maglic D; Sugiyama T; Morgan RL; Fry EA; Lagedrost SJ; Sui G; Inoue K
Cancer Res; 2012 Apr; 72(7):1740-50. PubMed ID: 22331460
[TBL] [Abstract][Full Text] [Related]
25. microRNA-1827 represses MDM2 to positively regulate tumor suppressor p53 and suppress tumorigenesis.
Zhang C; Liu J; Tan C; Yue X; Zhao Y; Peng J; Wang X; Laddha SV; Chan CS; Zheng S; Hu W; Feng Z
Oncotarget; 2016 Feb; 7(8):8783-96. PubMed ID: 26840028
[TBL] [Abstract][Full Text] [Related]
26. Lithocholic acid is an endogenous inhibitor of MDM4 and MDM2.
Vogel SM; Bauer MR; Joerger AC; Wilcken R; Brandt T; Veprintsev DB; Rutherford TJ; Fersht AR; Boeckler FM
Proc Natl Acad Sci U S A; 2012 Oct; 109(42):16906-10. PubMed ID: 23035244
[TBL] [Abstract][Full Text] [Related]
27. Growth suppression by a p14(ARF) exon 1beta adenovirus in human tumor cell lines of varying p53 and Rb status.
Saadatmandi N; Tyler T; Huang Y; Haghighi A; Frost G; Borgstrom P; Gjerset RA
Cancer Gene Ther; 2002 Oct; 9(10):830-9. PubMed ID: 12224024
[TBL] [Abstract][Full Text] [Related]
28. [Significance of MDM2 protein in the cell cycle].
Szemraj J; Rozpończyk E; Bartkowiak J; Greger J; Oszajca K
Postepy Biochem; 2005; 51(1):44-51. PubMed ID: 16209341
[TBL] [Abstract][Full Text] [Related]
29. Dynamics of ARF regulation that control senescence and cancer.
Ko A; Han SY; Song J
BMB Rep; 2016 Nov; 49(11):598-606. PubMed ID: 27470213
[TBL] [Abstract][Full Text] [Related]
30. The E2F1/Rb and p53/MDM2 pathways in DNA repair and apoptosis: understanding the crosstalk to develop novel strategies for prostate cancer radiotherapy.
Udayakumar T; Shareef MM; Diaz DA; Ahmed MM; Pollack A
Semin Radiat Oncol; 2010 Oct; 20(4):258-66. PubMed ID: 20832018
[TBL] [Abstract][Full Text] [Related]
31. Aberrant splicing of the DMP1-ARF-MDM2-p53 pathway in cancer.
Inoue K; Fry EA
Int J Cancer; 2016 Jul; 139(1):33-41. PubMed ID: 26802432
[TBL] [Abstract][Full Text] [Related]
32. The p53 mRNA-Mdm2 interaction controls Mdm2 nuclear trafficking and is required for p53 activation following DNA damage.
Gajjar M; Candeias MM; Malbert-Colas L; Mazars A; Fujita J; Olivares-Illana V; Fåhraeus R
Cancer Cell; 2012 Jan; 21(1):25-35. PubMed ID: 22264786
[TBL] [Abstract][Full Text] [Related]
33. Mouse double minute 2 associates with chromatin in the presence of p53 and is released to facilitate activation of transcription.
White DE; Talbott KE; Arva NC; Bargonetti J
Cancer Res; 2006 Apr; 66(7):3463-70. PubMed ID: 16585169
[TBL] [Abstract][Full Text] [Related]
34. Mdm2 and HIF-1alpha interaction in tumor cells during hypoxia.
Nieminen AL; Qanungo S; Schneider EA; Jiang BH; Agani FH
J Cell Physiol; 2005 Aug; 204(2):364-9. PubMed ID: 15880652
[TBL] [Abstract][Full Text] [Related]
35. ZBP-89 promotes growth arrest through stabilization of p53.
Bai L; Merchant JL
Mol Cell Biol; 2001 Jul; 21(14):4670-83. PubMed ID: 11416144
[TBL] [Abstract][Full Text] [Related]
36. TRIM25 has a dual function in the p53/Mdm2 circuit.
Zhang P; Elabd S; Hammer S; Solozobova V; Yan H; Bartel F; Inoue S; Henrich T; Wittbrodt J; Loosli F; Davidson G; Blattner C
Oncogene; 2015 Nov; 34(46):5729-38. PubMed ID: 25728675
[TBL] [Abstract][Full Text] [Related]
37. MDM2's dual mRNA binding domains co-ordinate its oncogenic and tumour suppressor activities.
Gnanasundram SV; Malbert-Colas L; Chen S; Fusée L; Daskalogianni C; Muller P; Salomao N; Fåhraeus R
Nucleic Acids Res; 2020 Jul; 48(12):6775-6787. PubMed ID: 32453417
[TBL] [Abstract][Full Text] [Related]
38. Targeting the MDM2/MDM4 interaction interface as a promising approach for p53 reactivation therapy.
Pellegrino M; Mancini F; Lucà R; Coletti A; Giacchè N; Manni I; Arisi I; Florenzano F; Teveroni E; Buttarelli M; Fici L; Brandi R; Bruno T; Fanciulli M; D'Onofrio M; Piaggio G; Pellicciari R; Pontecorvi A; Marine JC; Macchiarulo A; Moretti F
Cancer Res; 2015 Nov; 75(21):4560-72. PubMed ID: 26359458
[TBL] [Abstract][Full Text] [Related]
39. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53.
Parant J; Chavez-Reyes A; Little NA; Yan W; Reinke V; Jochemsen AG; Lozano G
Nat Genet; 2001 Sep; 29(1):92-5. PubMed ID: 11528400
[TBL] [Abstract][Full Text] [Related]
40. [Expression of proteins in p53 (p14ARF-mdm2-p53-p21WAF/CIP1) pathway and their significance in exocrine pancreatic carcinoma].
Yu GZ; Zhu MH; Ni CR; Li FM; Zheng JM; Gong ZJ
Zhonghua Bing Li Xue Za Zhi; 2004 Apr; 33(2):130-4. PubMed ID: 15132849
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
